Sionna Therapeutics (NASDAQ:SION) Director Sells $10,287,918.04 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 226,906 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04. Following the transaction, the director owned 3,020,119 shares of the company’s stock, valued at approximately $136,932,195.46. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total value of $84,237.30.

Sionna Therapeutics Price Performance

SION traded up $0.15 during trading on Thursday, reaching $45.24. 817,609 shares of the company were exchanged, compared to its average volume of 382,339. The firm has a 50 day moving average of $37.40 and a 200 day moving average of $38.18. Sionna Therapeutics, Inc. has a 52 week low of $9.39 and a 52 week high of $46.10.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. TD Asset Management Inc lifted its position in shares of Sionna Therapeutics by 74.3% during the 3rd quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock worth $2,561,000 after buying an additional 37,116 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Sionna Therapeutics in the 3rd quarter valued at $147,000. Artia Global Partners LP bought a new position in Sionna Therapeutics in the 4th quarter valued at $4,926,000. Eventide Asset Management LLC bought a new position in Sionna Therapeutics in the 4th quarter valued at $26,290,000. Finally, ProShare Advisors LLC bought a new position in Sionna Therapeutics in the 4th quarter valued at $202,000.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Guggenheim lifted their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.